| 引用本文: |
徐维国,崔蓉,岳崇梅,吴君华,李丹,谢佳俊.慢性阻塞性肺病患者β2-AR基因多态性与复方薤白胶囊疗效的相关性研究[J].湖南中医药大学学报,2018,38(12):1440-1443[点击复制] |
|
| |
|
|
| 本文已被：浏览 2667次 下载 1295次 |
| 慢性阻塞性肺病患者β2-AR基因多态性与复方薤白胶囊疗效的相关性研究 |
| 徐维国,崔蓉,岳崇梅,吴君华,李丹,谢佳俊 |
| (绵阳市中心医院, 四川 绵阳 621000) |
| 摘要: |
| 目的 研究慢性阻塞性肺病（COPD）患者β2-肾上腺素受体（β2-AR）编码区16、27位点基因多态性与复方薤白胶囊疗效的相关性。方法 选择2015年1月至2018年1月本院收治的COPD患者210例，均进行基因突变类型测序和复方薤白胶囊治疗，分别于治疗前、治疗第3天和第7天进行第1秒用力呼气量（FEV1）检测，并于治疗前、治疗第7天和第14天进行圣乔治呼吸问卷（SGRQ）调查及慢性阻塞性肺疾病评估测试（CAT）。结果 210例患者根据基因型分为野生型纯合子组97例、野生型与突变型基因杂合子组83例、突变型基因纯合子或杂合子组30例。治疗第3天和第7天，3组FEV1水平均显著升高且组间有差异（P<0.05），其中野生型纯合子组>野生型与突变型基因杂合子组>突变型基因纯合子或杂合子组（P<0.05）。治疗第7天和第14天，3组SGRQ评分及CAT评分均显著降低且组间有差异（P<0.05），其中野生型纯合子组低于野生型与突变型基因杂合子组及突变型基因纯合子或杂合子组（P<0.05）。结论 β2-AR基因多态性会影响复方薤白胶囊疗效。 |
| 关键词: 慢性阻塞性肺病 β2-肾上腺素受体 基因多态性 复方薤白胶囊 |
| DOI：10.3969/j.issn.1674-070X.2018.12.020 |
| 投稿时间：2018-05-16 |
| 基金项目:四川省绵阳市卫生局科研计划（201314）。 |
|
| Association Between β2-Adrenergic Receptor Gene Polymorphisms and Clinical Outcome in Patients with Chronic Obstructive Pulmonary Disease Treated with Compound Xiebai Capsule |
| XU Weiguo,CUI Rong,YUE Chongmei,WU Junhua,LI Dan,XIE Jiajun |
| (Mianyang Central Hospital, Mianyang, Sichuan 621000, China) |
| Abstract: |
| Objective To investigate the association of the polymorphisms of loci 16 and 27 of β2-adrenergic receptor (β2-AR) coding region with the clinical outcome of patients with chronic obstructive pulmonary disease (COPD) treated with Compound Xiebai Capsule.Methods A total of 210 patients with COPD who were admitted to our hospital from January 2015 to January 2018 were enrolled and treated with Compound Xiebai Capsule. Gene mutation detection and sequencing were performed for all patients. Forced expiratory volume in 1 second (FEV1) was measured before treatment and on days 3 and 7 of treatment, and St. George's Respiratory Questionnaire (SGRQ) survey and COPD assessment test (CAT) were conducted before treatment and on days 7 and 14 of treatment.Results According to the genotype, 210 patients were divided into wild-type homozygote group with 97 patients, wild-mutant heterozygote group with 83 patients, and mutant homozygote/heterozygote group with 30 patients. On days 3 and 7 of treatment, the three groups had a significant increase in FEV1 and there was a significant difference between these groups (P<0.05); the wild-type homozygote group had the highest FEV1, followed by the wild-mutant heterozygote group and the mutant homozygote/heterozygote group (P<0.05). On days 7 and 14 of treatment, the three groups had significant reductions in SGRQ and CAT scores and there were significant differences between these groups (P<0.05); the wild-type homozygote group had significantly lower scores than the wild-mutant heterozygote group and the mutant homozygote/heterozygote group (P<0.05).Conclusion β2-AR gene polymorphisms will affect the clinical outcome of patients treated with Compound Xiebai Capsule. |
| Key words: chronic obstructive pulmonary disease β2-adrenergic receptor gene polymorphism Compound Xiebai Capsule |
|
二维码（扫一下试试看！） |
|
|
|
|
